Glaukos (NYSE:GKOS) CFO Sells $3,602,600.00 in Stock

Posted by on Aug 11th, 2026

Glaukos Corporation (NYSE:GKOS – Get Free Report) CFO Alex Thurman sold 20,000 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $180.13, for a total value of $3,602,600.00. Following the transaction, the chief financial officer directly owned 43,906 shares in the company, valued at $7,908,787.78. This represents a 31.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Glaukos Price Performance

Glaukos stock traded up $1.55 during midday trading on Tuesday, reaching $182.97. The company’s stock had a trading volume of 723,278 shares, compared to its average volume of 883,314. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $184.00. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04. The stock’s 50 day simple moving average is $145.79 and its 200 day simple moving average is $127.64. The firm has a market capitalization of $10.79 billion, a PE ratio of -56.30 and a beta of 0.78.

Glaukos (NYSE:GKOS – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. The business had revenue of $185.61 million during the quarter, compared to the consensus estimate of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The business’s revenue was up 49.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.24) EPS. On average, equities research analysts forecast that Glaukos Corporation will post -0.35 earnings per share for the current year.

Hedge Funds Weigh In On Glaukos

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Horizon Corp lifted its holdings in shares of Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 223 shares in the last quarter. Allworth Financial LP acquired a new stake in shares of Glaukos in the second quarter valued at approximately $28,000. Los Angeles Capital Management LLC purchased a new position in shares of Glaukos during the 4th quarter worth approximately $28,000. Larson Financial Group LLC increased its stake in shares of Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 132 shares in the last quarter. Finally, Parallel Advisors LLC raised its position in shares of Glaukos by 159.2% during the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 226 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. JPMorgan Chase & Co. boosted their price target on Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. HC Wainwright raised their price objective on Glaukos from $168.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Stifel Nicolaus lifted their price objective on Glaukos from $175.00 to $190.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Citigroup lifted their price objective on Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, Piper Sandler reiterated an “overweight” rating and set a $195.00 target price (up from $165.00) on shares of Glaukos in a research report on Thursday, July 30th. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $177.33.

Check Out Our Latest Stock Analysis on Glaukos

Glaukos Company Profile

(Get Free Report)

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

Featured Articles

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.